Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma

Leukemia and Lymphoma

Volumn 43, Issue 12, 2002, Pages 2427-2430

  Potti, Anil ^a   Ganti, Apar Kishor ^a   Koch, Michael ^b   Levitt, Ralph ^c   Mehdi, Syed ^d  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

^b MeritCare Hospital   (United States)

^c MeritCare Roger Maris Cancer Center   (United States)

^d Fargo VA Medical Center   (United States)

Author keywords

c Kit; HER 2 neu overexpression; Multiple myeloma; Outcome

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ONCOGENE NEU; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE SIZE; SIGNAL TRANSDUCTION; BIOSYNTHESIS; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0036891253     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000040198     Document Type: Letter

References (30)

1. Bergsagel, D.E. (1988) "Use a gentle approach for refractory myeloma patients", Journal of Clinical Oncology 6, 757-758.
2. Griffin, J. (2001) "The biology of signal transduction inhibition: basic science to novel therapies", Seminars in Oncology 28(5 Suppl. 17), 3-8.
3. Hung, M.C. and Lau, Y.K. (1999) "Basic science of HER-2/neu: a review", Seminars in Oncology 12(Suppl. 12), 51-59.
4. Schneider, P.M., Hung, M.C., Chiocca, S.M., Manning, J., Zhao, X.Y., Fang, K. and Roth, J.A. (1989) "Differential expression of the c-erbB-2 gene in human small cell and non-small lung cell cancer", Cancer Research 49, 4968-4971.
5. Weiner, D.B., Nordberg, J., Robinson, R., Nowell, P.C., Gazdar, A., Greene, M.I., Williams, W.V., Cohen, J.A. and Kern, J.A. (1990) "Expression of neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung", Cancer Research 50, 421-425.
6. Potti, A., Willardson, J., Forseen, C., Ganti, A.K., Koch, M., Hebert, B., Levitt, R. and Mehdi, S.A. (2002) "Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma", Lung Cancer, 36, 257-261.
7. Zhang, X., Silva, E., Greshenson, D. and Hung, M.C. (1989) "Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract", Oncogene 4, 985-989.
8. Yokota, J., Yamamoto, T., Miyajima, N., Toyoshima, K., Nomura, N., Sakamoto, H., Yoshida, T., Terada, M. and Sugimura, T. (1988) "Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue", Oncogene 2, 283-287.
9. Riben, M.W., Malfetano, J.H., Nazeer, T., Muraca, P.J., Ambros, R.A. and Ross, J.S. (1997) "Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma", Modern Pathology 10, 823-831.
10. Costa, M.J. and Walls, J. (1996) "Epidermal growth factor receptor and c-erbB-2oncoprotein expression in female genital tract carcinosarcomas (malignant mixed Mullerian tumors). Clinico-pathologic study of 82 cases", Cancer 77, 533-542.
11. Dugan, M.C., Dergham, S.T., Kucway, R., Singh, K., Biernat, L., Du, W., Vaitkevicius, V.K., Crissman, J.D. and Sarkar, F.H. (1997) "HER-2/neu expression in pancreatic adenocarcinoma: Relation to tumor differentiation and survival", Pancreas 14, 229-236.
12. Kapitanovic, S., Radosevic, S., Kapitanovic, M., Andelinovic, S., Ferencic, Z., Tavassoli, M., Primorac, D., Sonicki, Z., Spaventi, S., Pavelic, K. and Spaventi, R. (1997) "The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer", Gastroenterology 112, 1103-1113.
13. Costa, M.J., Walls, J. and Trelford, J.D. (1995) "C-erbB-2 oncoprotein over-expression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease", American Journal of Clinical Pathology 104, 634-642.
14. Mellemgaard, A., Geisler, C.H. and Storm, H.H. (1994) "Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemias", European Journal of Haematology 53, 218-222.
15. Yu, D., Liu, B., Tan, M., Li, J., Wang, S.S. and Hung, M.C. (1996) "Over-expression of c-erbB-2/neu I breast cancer cells confers increased resistance to Taxo1 via mdr-1-independent mechanisms", Oncogene 13, 1359-1365.
16. McCann, A.H., Dervan, P.A., O'Regan, M., Codd, M.B., Gullick, W.J., Tobin, B.M. and Carney, D.N. (1991) "Prognostic significance of c-erb B-2 and estrogen receptor status in human breast cancer", Cancer Research 51, 3296-3303.
17. Slamon, D.J., Clark, G.K., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) "Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene", Science 235, 177-182.
18. Gusterson, B.A., Gelber, R.D., Goldhirsch, A., Price, K.N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C.M., Golouh, R. and Reed, R. (1992) "Prognostic importance of c-erb B-2 expression in breast cancer International (Ludwig) Breast Cancer Study Group", Journal of Clinical Oncology 10, 1049-1056.
19. Cobleigh, M.A., Fehrenbacher, L., Lieberman, G., Paton, V., Robert, N.J., Scholl, S., Shak, S., Slamon, D., Tripathy, D. and Vogel, C.L. (1998) "Efficacy and safety of Herceptin as a single agent in 222 women with HER-2 overexpression who relapsed following chemotherapy for metastatic breast cancer", Proceedings of the American Society of Clinical Oncology 17, 97a(abstr).
20. Potti, A., Ganti, A.K., Koch, M., Mehdi, S.A. and Levitt, R., (2001) "Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia", Lung Cancer 34, 227-232.
21. Demetri, G.D. (2001) "Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options", Seminars in Oncology 17(5 Suppl. 17), 19-26.
22. Lemoli, R.M. and Fortuna, A. (1996) "C-kit ligand (SCF) in human multiple myeloma cells", Leukemia and Lymphoma 20, 457-464.
23. van Oosterom, A.T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., Silberman, S., Nielsen, O.S. and European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2001) "Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study", Lancet 358, 1421-1423.
24. Bluehler, H., Bangemann, N., Evers, K., Becker, C. and Schaller, G. (2000) "Effective HER-2/neu diagnosis in breast cancer by a combination of immunochemistry and FISH", Proceedings of the American Society of Clinical Oncology 19, 76a(abstr).
25. Mass, R.D., Sanders, C., Charlene, K., Johnson, L., Everett, T. and Anderson, S. (2000) "The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials", Proceedings of the American Society of Clinical Oncology 19, 75a(abstr).
26. Fourney, R., Palmer, M., Ng, A., Dietrich, K., Belch, A., Paterson, M. and Brox, L. (1990) "Elevated c-myc messenger RNA in multiple myeloma cell lines", Disease Markers 3, 117-124.
27. Escribano, L., Ocqueteau, M., Almeida, J., Orfao, A. and San Miguel, J.F. (1998) "Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis", Leukemia and Lymphoma 30, 459-466.
28. Gooding, R.P., Bybee, A., Cooke, F., Little, A., Marsh, S.G., Coelho, E., Gupta, D., Samson, D. and Apperley, J.F. (1999) "Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia", British Journal of Haematology 106, 669-681.
29. Lemoli, R.M., Fortuna, A., Grande, A., Gamberi, B., Bonsi, L., Fogli, M., Amabile, M., Cavo, M., Ferrari, S. and Tura, S. (1994) "Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells", British Journal of Haematology 88, 760-769.
30. Ocqueteau, M., Orfao, A., Garcia-Sanz, R., Almeida, J., Gonzalez, M. and San Miguel, J.F. (1996) "Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells", British Journal of Haematology 95, 489-493.